Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 105
- Registration Number
- NCT06716424
- Locations
- 🇮🇳
Investigational Site Number : 3560009, Bengaluru, India
🇮🇳Investigational Site Number : 3560011, Jaipur, India
🇮🇳Investigational Site Number : 3560008, Pune, India
A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3500
- Registration Number
- NCT06714448
- Locations
- 🇫🇷
Sanofi-Aventis, Chilly-Mazarin, France
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3500
- Registration Number
- NCT06714461
- Locations
- 🇫🇷
Sanofi-Aventis, Chilly-Mazarin, France
A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT06704932
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 670
- Registration Number
- NCT06694025
- Locations
- 🇰🇷
Investigational Site 001, Seoul, Korea, Republic of
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 980
- Registration Number
- NCT06695130
- Locations
- 🇺🇸
Synexus Clinical Research US, Inc. - Cerritos- Site Number : 8400002, Cerritos, California, United States
🇺🇸Central Phoenix Medical Clinic- Site Number : 8400009, Phoenix, Arizona, United States
🇺🇸Synexus Clinical Research US - Vista- Site Number : 8400010, Vista, California, United States
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 980
- Registration Number
- NCT06695117
- Locations
- 🇺🇸
Simon Williamson Clinic - Birmingham- Site Number : 8400003, Birmingham, Alabama, United States
🇺🇸AES - DRS - Optimal Research Alabama - Huntsville Site Number : 8400006, Huntsville, Alabama, United States
🇺🇸Orange Grove Family Practice- Site Number : 8400012, Tucson, Arizona, United States
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06695897
- Locations
- 🇩🇪
Investigational Site Number: 0000001, Dachau, Bayern, Germany
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
- Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT06691113
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 136
- Registration Number
- NCT06687980
- Locations
- 🇺🇸
Austin Institute for Clinical Research - Pflugerville- Site Number : 8400203, Pflugerville, Texas, United States
🇺🇸Progressive Clinical Research - San Antonio- Site Number : 8400206, San Antonio, Texas, United States
🇨🇦Investigational Site Number : 1240205, London, Ontario, Canada